Pearse, Roger N

Publications

Sort by

Co-Author Network

selected publications

Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma. Blood advances. 2024 Academic Article GET IT
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. Frontiers in oncology. 2022 Review GET IT
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma. American journal of hematology. 2021 Academic Article GET IT
Times cited: 1
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 1
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood cancer discovery. 2020 Academic Article GET IT
Sequence matters: elotuzumab more effective if used before daratumumab. Leukemia & lymphoma. 2019 Article GET IT
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone marrow transplantation. 2019 Academic Article GET IT
Times cited: 12
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood advances. 2019 Academic Article GET IT
Times cited: 12
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. American journal of hematology. 2019 Academic Article GET IT
Times cited: 2
Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leukemia & lymphoma. 2018 Academic Article GET IT
Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 15
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. Clinical lymphoma, myeloma & leukemia. 2017 Academic Article GET IT
Times cited: 7
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Academic Article GET IT
Times cited: 7
Haplo-cord transplant: HLA-matching determines graft dominance. Leukemia & lymphoma. 2016 Letter GET IT
Times cited: 9
Cord blood chimerism and relapse after haplo-cord transplantation. Leukemia & lymphoma. 2016 Academic Article GET IT
Times cited: 19
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical lymphoma, myeloma & leukemia. 2016 Academic Article GET IT
Times cited: 10
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 7
A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone marrow transplantation. 2014 Letter GET IT
Times cited: 10
IMiDs: Not for the CRBN weak. Leukemia research. 2013 Editorial Article GET IT
Times cited: 4
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 12
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 30
Age matters: Young T lymphocytes offer better protection from myeloma proliferation. Immunity & ageing : I & A. 2013 Academic Article GET IT
Times cited: 1
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 20
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Academic Article GET IT
Times cited: 32
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American journal of hematology. 2012 Letter GET IT
Times cited: 33
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 89
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. American journal of hematology. 2010 Academic Article GET IT
Times cited: 46
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. British journal of haematology. 2008 Academic Article GET IT
Times cited: 50
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008 Academic Article GET IT
Times cited: 103
New strategies for the treatment of metastatic bone disease. Clinical breast cancer. 2007 Information Resource GET IT
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma. 2007 Academic Article GET IT
Times cited: 53
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2007 Academic Article GET IT
Times cited: 161
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. British journal of haematology. 2007 Academic Article GET IT
Times cited: 79
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Conference Paper GET IT
Times cited: 18
Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Information Resource GET IT
Times cited: 14
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005 Academic Article GET IT
Times cited: 109
RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis : an international journal on programmed cell death. 2004 Academic Article GET IT
Times cited: 14
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 62
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. British journal of haematology. 2002 Academic Article GET IT
Times cited: 292
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 2001 Academic Article GET IT
Times cited: 445
SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity. 1999 Academic Article GET IT
Times cited: 178
SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity. 1998 Academic Article GET IT
Times cited: 312
Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone marrow transplantation. 1996 Academic Article GET IT
Times cited: 52
PU.1 and an HLH family member contribute to the myeloid-specific transcription of the Fc gamma RIIIA promoter. The EMBO journal. 1994 Academic Article GET IT
Times cited: 84
Sperm 1: a POU-domain gene transiently expressed immediately before meiosis I in the male germ cell. Proceedings of the National Academy of Sciences of the United States of America. 1993 Academic Article GET IT
Times cited: 48
Interferon gamma-induced transcription of the high-affinity Fc receptor for IgG requires assembly of a complex that includes the 91-kDa subunit of transcription factor ISGF3. Proceedings of the National Academy of Sciences of the United States of America. 1993 Academic Article GET IT
Times cited: 182
Characterization of the promoter of the human gene encoding the high-affinity IgG receptor: transcriptional induction by gamma-interferon is mediated through common DNA response elements. Proceedings of the National Academy of Sciences of the United States of America. 1991 Academic Article GET IT
Times cited: 165
Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. Science (New York, N.Y.). 1990 Academic Article GET IT
Times cited: 247
The noradrenergic system in cultured aggregates of fetal rat brain cells: morphology of the aggregates and pharmacological indices of noradrenergic neurons. Brain research. 1981 Academic Article GET IT
Times cited: 8

more ...

less ...

Background

education and training

Ph.D., Cornell University 91
M.D., Cornell University Medical College 1986
B.A., Dartmouth College 1977

Contact

full name

Roger N Pearse

primary email

rnp2001@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Roger N Pearse Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage